Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, has been named an Emerald honoree at the 2026 Pinnacle Awards for Healthcare, recognizing its innovative approach to addressing cancer drug resistance. The award underscores the company's strategy of developing resistance-modulating treatments, particularly its lead candidate ENV-105 (carotuximab), designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies.
The Pinnacle Awards, which honor excellence in healthcare innovation, selected Kairos Pharma for its work in overcoming one of the most persistent challenges in oncology: drug resistance. Many cancer treatments initially show promise but lose efficacy over time as tumors develop resistance. Kairos Pharma's approach targets this problem by focusing on CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105, an antibody targeting CD105, aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is being evaluated in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, both indications with significant unmet medical needs. The company is advancing combination approaches aimed at improving durability of response, potentially offering new hope for patients who have limited treatment options after standard therapies fail.
Kairos Pharma's recognition at the 2026 Pinnacle Awards highlights the potential impact of its research. The award not only validates the company's scientific approach but also draws attention to the critical issue of drug resistance in oncology. As cancer treatments evolve, addressing resistance mechanisms is increasingly seen as essential for improving long-term patient outcomes. By targeting CD105, Kairos Pharma is pursuing a novel pathway that could complement existing therapies and extend their effectiveness.
The company's work is particularly relevant given the growing understanding that drug resistance is a major factor in cancer mortality. Traditional approaches often focus on developing new drugs to replace those that fail, but Kairos Pharma's strategy aims to extend the utility of existing treatments, potentially reducing the need for costly and time-consuming development of entirely new agents. This could have significant implications for healthcare systems and patients alike, offering a more efficient path to better outcomes.
Kairos Pharma is based in Los Angeles, California, and utilizes structural biology to overcome drug resistance and immune suppression in cancer. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. The company's progress in clinical trials will be closely watched by the oncology community, as the potential for ENV-105 to address drug resistance could represent a meaningful advance in cancer care.
